Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-09
2006-05-09
Graser, Jennifer E. (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S009000, C435S009000
Reexamination Certificate
active
07041466
ABSTRACT:
Compositions and methods are provided for evaluating the progress of disease induced by infection withChlamydiaspp. Specifically, the invention provides a mouse lung disease model of infection withChlamydiaspp. bacteria. The compositions and methods of the invention find use in evaluating the efficacy of vaccines and other therapeutic or prophylactic treatments ofChlamydia-induced disease.
REFERENCES:
patent: 5324668 (1994-06-01), Macri
Campbell, L.A. et al. 1998. Preclinical models forChlamydia pneumoniaeand cardiovascular disease: hypercholesterolemic mice. Clin. Microbial. Infect. 4(supp. 4): S23-S32.
Yang, Z. et al. 1993. A Mouse Model ofChlamydia pneumoniaeStrain TWAR Pneumonitis. Infect. Immun. 61(5): 2037-2040.
Huang, J. et al. Mar. 19, 2002. The quantity of nitric oxide relesaed by macrophages regulatesChlamydia-induced disease. P.N.A.S. 99(6): 3914-3919.
Allione, et al., “Nitric Oxide Suppresses Human T Lymphocyte Proliferation Through IFN-γ-Dependent and IFN-γ-Independent Induction of Apoptosis,”The Journal of Immunology, 1999, pp. 4182-4191, vol. 163.
Chang, et al., “Arginase Modulates Nitric Oxide Production in Activated Macrophases,”Am. J. Physiol., 1998, pp. H342-H348.
Dalton, et al., “Interferon γ Eliminates Responding CD4 T Cells during Mycobacterial Infection by Inducing Apoptosis of Activated CD4 T Cells,”J. Exp. Med., 2000, pp. 117-122, vol. 192(1).
Detmers, et al., “Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice,”The Journal of Immunology, 2000, pp. 3430-3435, vol. 165.
Diefenbach, et al., “Requirement for Type 2 NO Synthase for IL-12 Signaling in Innate Immunity,”Science, 1999, pp. 951-955, vol. 284.
Gantt, et al., “Oxidative Responses of Human and Murine Macrophages During Phagocytosis ofLeishmania chagasi,” The Journal of Immunology, 2001, pp. 893-901, vol. 167.
Gotoh, T. and Morj, M., “Arginase II Downregulates Nitric Oxide (NO) Production and Prevents NO-mediated Apoptosis in Murine Macrophage-derived RAW 264.7 Cells,”The Journal of Cell Biology, 1999, pp. 427-434, vol. 144, No. 3.
Guo, et al., “Molecular Mechanisms of Increased Nitric Oxide (NO) in Asthma: Evidence for Transcriptional and Post-Translational Regulation of NO Synthesis,”The Journal of Immunology, 2000, pp. 5970-5980, vol. 164.
Herrick, C.A. and Bottomly, K., “To Respond or Not To Respond: T Cells in Allergic Asthma,”Nature Reviews/Immunology, 2003, pp. 1-8, vol. 3.
Holland, et al., “Conjunctival Scarring in Trachoma Is Associated with Depressed Cell-Mediated Immune Responses toChlamydialAntigens,”The Journal of Infectious Diseases, 1993, pp. 1528-1531, vol. 168.
Hu, et al., “The Artherogenic Effects ofChlamydiaare Eependent on Serum Cholesterol and Specific toChlamydia pneumoniae,” Journal of Clinical Investigation., 1999, pp. 747-753, vol. 103(5).
Huang, et al., “Nitric Oxide Regulates Th1 Cell Development Through the Inhibition of IL-12 Synthesis by Macrophages,”Eur. J. Immunol., 1998, pp. 4062-4070, vol. 28.
Huang, et al., “IL-12 Administered DuringChlamydia psittaciLung Infection in Mice Confers Immediate and Long-Term Protection and Reduces Macrophage Inflammatory Protein-2 Level and Neutrophil Infiltration in Lung Tissue,”The Journal of Immunology, 1999, pp. 2217-2226, vol. 162.
Huang, et al., “The Quantity of Nitric Oxide Released by Macrophages RegulatesChlamydia-induced Disease,”PNAS, 2002, pp. 3914-3919, vol. 99(6).
Igietseme, et al., “Resolution of MurineChlamydialGenital Infection by the Adoptive Transfer of a Biovar-Specific, TH1Lymphocyte Clone,”Regional Immunology, 1993, pp. 317-324, vol. 5.
Igietseme, et al., “ChlamydialInfection in Inducible Nitric Oxide Synthase Knockout Mice,”Infection and Immunity, 1998, pp. 1282-1286, vol. 66(4).
Mori, M. and Gotoh, T., “Relationship between Arginase Activity and Nitric Oxide Production,” Chapter 12,Nitric Oxide Biology and Pathiobiology, 2000, Chapter 12, pp. 199-208.
Jackson, et al., “Specificity of Detection ofChlamydia pneumoniaein Cardiovascular Atheroma,”American Journal of Pathology, 1997, pp. 1785-1790, vol. 150(5).
Kaltenböck, et al., “Genetically Determined Vigorous Innate Immunity is Associated with Protection Against PrimaryChlamydialLung Infection in Mice, but with Profound Disease Exacerbation in Reinfection,”Chlamydial Infections, Proceedings of the Ninth International Symposium on HumanChlamydialInfection, Jun. 21-26, 1998, pp. 403-406.
Lyons, et al., “Molecular Cloning and Functional Expression of an Inducible Nitric Oxide Synthase from a Murine Macrophage Cell Line,”The Journal of Biological Chemistry, 1992, pp. 6370-6374, vol. 267(9).
Macmicking, et al., “Nitric Oxide and Macrophage Function,”Annu. Rev. Immunol., 1997, pp. 323-350, vol. 15.
Magee, et al., “Chlamydia trachomatisPneumonia in the Severe Combined Immunodeficiency (SCID) Mouse,”Regional Immunology, 1993, pp. 305-311, vol. 5(6).
Mills, et al., “M-1/M-2 Macrophages and the Th1/Th2 Paradigm,”The Journal of Immunology, 2000, pp. 6166-6173, vol. 164.
Moazed, et al., “Evidence of Systemic Dissemination ofChlamydia pneumoniaevia Macrophages in the Mouse,”The Journal of Infectious Diseases, 1998, pp. 1322-1325, vol. 177.
Moazed, et al., “Chlamydia pneumoniaeInfection Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice,”The Journal of Infectious Diseases, 1999, pp. 238-241, vol. 180.
Morrison, et al., “Gene Knockout Mice Establish a Primary Protective Role for Major Hisocompatibility Complex Class II-Restricted Responses inChlamydia trachomatisGenital Tract Infection,”Infection and Immunity, 1995, pp. 4661-4668, vol. 63(12).
Munder, et al., “Th1/Th2-Regulated Expression of Arginase Isoforms in Murine Macrophages and Dendritic Cells,”The Journal of Immunology, 1999, pp. 3771-3777, vol. 163.
Oswald, et al., “Low Response of BALB/c marophages to Priming and Activating Signals,”Journal of Leukocyte Biology, 1992, pp. 315-322, vol. 52.
Perry, et al., “Neither Interleukin-6 nor Inducible Nitric Oxide Synthase is Required for Clearance ofChlamydia trachomatisfrom the Murine Genital Tract Epithelium,”Infection and Immunity, 1998, pp. 1265-1269, vol. 66(3).
Ramsey, et al., “Chlamydia trachomatisPersistance in the Female Mouse Genital Tract: Inducible Nitric Oxide Synthase and Infection Outcome,”Infection and Immunity, 2001, pp. 5131-5137, vol. 69(8).
Rank, R.G., “Models of Immunity,”Chlamydia: Intracellular Biology, Pathogenesis, and Immunity, 1999, Chapter 9, pp. 239-295.
Ross, R., “Atherosclerosis—An Inflammatory Disease,”Mechanisms of Disease, 1999, pp. 115-126, vol. 340(2).
Rottenberg, et al., “Role of Innate and Adaptive Immunity in the Outcome of Primary Infection withChlamydia pneumoniae, as Analyzed in Genetically Modified Mice,”The Journal of Immunology, 1999, pp. 2829-2836, vol. 162.
Schachter, J., “Infection and Disease Epidemiology,”Chlamydia: Intracellular Biology, Pathogenesis, and Immunity, 1999, Chapter 6, pp. 139-169.
Schwacha, M.G. and Eisenstein, T.K., “Interleukin-12 is Critical for Induction of Nitric Oxide-Mediated Immunosuppression following Vaccination of Mice with AttenuatedSalmonella typhimurium,” Infection and Immunity, 1997, pp. 4897-4903, vol. 65(12).
Schwacha, et al., “Salmonella typhimuriumInfection in Mice Induces Nitric Oxide-Mediated Immunosuppression through a Natural Killer Cell-Dependent Pathway,”Infection and Immunity, 1998, pp. 5862-5866, vol. 66(12).
Stevenson, et al., “Genetic Linkage of Reistance toListeria Monocytogeneswith Macrophage Inflammatory Responses,”The Journal of Immunology, 1981, p
Huang Jin
Kaltenboeck Bernhard
Alston & Bird LLP
Auburn University
Graser Jennifer E.
LandOfFree
Mouse disease model for evaluation of prophylactic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mouse disease model for evaluation of prophylactic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mouse disease model for evaluation of prophylactic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3566354